Table 1 Characteristics of the IgG4-RD, SSc, and control cohorts used in the study. Other treatments include mycophenolate mofetil, methotrexate, hydroxychloroquine, abatacept, cyclophosphamide, azathioprine, tocilizumab, and etanercept. RTX rituximab, lcSSc limited cutaneous, dcSSc diffuse cutaneous, ssSSc sine scleroderma, osSSc overlap scleroderma

From: Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis